Biologic agents, including monoclonal antibodies targeting interleukin-13 (IL-13) such as dupilumab, have shown efficacy in reducing periostin levels and improving asthma control in patients with severe eosinophilic asthma. This evidence concerns the gene POSTN and asthma.